Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
Anas Younes(Memorial Sloan Kettering Cancer Center), Andreas Engert(University Hospital Cologne), Patrick B. Johnston(City Of Hope National Medical Center), Anna Sureda(Institut Català d'Oncologia), Pier Luigi Zinzani(University of Bologna), Simon J. Harrison(The University of Melbourne), Jennifer Gallagher(City Of Hope National Medical Center), Angela Shen(City Of Hope National Medical Center), Tee-Chuan Ong(City Of Hope National Medical Center), Dina Ben‐Yehuda(Hadassah Medical Center), H. Miles Prince(Monash University), Christophe Le Corre(City Of Hope National Medical Center), Mark Kirschbaum(City of Hope)
Cited by 261
Related Papers
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657